Every material Form 8-K Connect Biopharma Holdings Ltd has filed with the SEC since August 12, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Connect Biopharma reported preliminary topline results from its Phase 2 Seabreeze STAT COPD study of rademikibart as an add-on treatment for acute COPD exacerbations, with 159 participants randomized 1:1. The primary endpoint, treatment failure through Week 4, was reduced 81% versus placebo (p=0.0122), but the key secondary FEV1 result at Week 4 (70 mL improvement, p=0.1607) was not statistically significant. The company plans to engage the FDA on a Phase 3 program, and no timing was given.
Treatment failure through Week 4 was reduced 81% versus placebo (p=0.0122); 2 of 78 rademikibart participants and 11 of 81 placebo participants experienced treatment failure
FEV1 improved 70 mL at Week 4 versus placebo, but the result was not statistically significant (p=0.1607)
Any treatment-emergent adverse event occurred in 11 (14.1%) rademikibart participants versus 21 (25.9%) placebo participants
Connect plans to engage the FDA on a Phase 3 program; the filing gives no timing for that engagement
Connect Biopharma reported topline results from its 160-patient Phase 2 Seabreeze STAT Asthma study of rademikibart as an add-on to standard of care for acute asthma exacerbations. The primary endpoint, treatment failure over 28 days, did not reach statistical significance (p=0.153), although the company reported a 66% reduction versus placebo, while the key secondary endpoint, post-bronchodilator FEV1 at Day 7, was statistically significant (p=0.023). The company plans to report COPD study data later this month and then meet with the FDA on a Phase 3 program.
Treatment failure rate over 28 days was 2.5% (2 of 79) with rademikibart versus 7.4% (6 of 81) with placebo; p=0.153, not statistically significant
Post-bronchodilator FEV1 on Day 7 rose 250 mL with rademikibart versus 120 mL with placebo, a 130 mL difference (p=0.023)
One serious adverse event was reported in the rademikibart arm versus three in the placebo arm; no AEs led to study discontinuation in either arm
Seabreeze STAT COPD study topline data expected later in September 2026; company plans to engage the FDA on a Phase 3 program afterward
Connect Biopharma reported results for the three and six months ended June 30, 2026. Revenue rose to $2.8 million for the quarter, mainly from a regulatory milestone under its Simcere license, but the net loss widened to $17.3 million, or $0.27 per share, from $12.9 million, or $0.23 per share, a year earlier, as research and development expense nearly doubled. The company said its $31.5 million in cash, cash equivalents and short-term investments should fund operations for at least one year from the release date, and it expects topline data from its two Phase 2 Seabreeze STAT studies in September 2026.
Q2 2026 license and collaboration revenue was $2.8 million, versus $48,000 in Q2 2025, primarily from a regulatory-based milestone net of development cost sharing.
Q2 2026 research and development expense was $16.3 million, up from $8.8 million, mainly due to rademikibart development costs for the Seabreeze STAT studies.
Q2 2026 net loss was $17.3 million, or $0.27 per share, compared with $12.9 million, or $0.23 per share, in Q2 2025.
Cash, cash equivalents and short-term investments were $31.5 million as of June 30, 2026, down from $44.3 million at December 31, 2025; topline data from the Phase 2 studies are expected in September 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Connect Biopharma Holdings Ltd filing is on SEC EDGAR ↗. 8-K briefs of other companies →